

ROMINAZIT

1. Product Name

Generic name: Azithromycin 500 mg & Brand name: Rominazit

2. Name and Strength of Active Ingredient(s): Azithromycin 500 mg

3. Product Description: Rominazit (Azithromycin 500 mg);
Hard gelatin capsules with white body and pink cap.

4. Pharmacodynamics/Pharmacokinetics

Pharmacodynamic properties

Pharmacotherapeutic group - Anti-infectious agents for systemic use, macrolides.

ATC code: J01FA10

Mechanism of action

Azithromycin is a macrolide antibiotic belonging to the azalide group. The mechanism of action of azithromycin is based mainly upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50s sub-unit and inhibition of peptide translocation.

Pharmacological effects

Azithromycin is active against a large number of microorganisms causing some common human diseases - Aerobic Gram+ and Gram- microorganisms (*Staphylococcus aureus*, *Haemophilus influenzae*, Methylcellin-susceptible *Streptococcus pneumoniae*, *Legionella pneumophila*, Penicillin-susceptible *Streptococcus pyogenes* (Group A), *Moraxella catarrhalis* and etc.), Anaerobic microorganisms (*Clostridium perfringens*, *Fusobacterium spp.*, *Prevotella spp.* and etc.) and *Chlamydia trachomatis*.

Pharmacokinetic properties

Absorption: Peak plasma concentrations are attained 2-3 hours after administration.

Distribution: Orally administered azithromycin is intensively and widely distributed throughout the body. It has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in blood.

Biotransformation: Ten metabolites were detected which are not microbiologically active.

Elimination: Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in urine within the following 3 days. Particularly high concentrations of unchanged azithromycin have been found in human bile.

5. Indication

Rominazit is indicated in adults and children weighing more than 45 kg for the treatment of infections known or suspected to have been caused by one or more azithromycin-susceptible microorganisms:

- Upper respiratory tract infections - pharyngitis/tonsillitis, sinusitis and otitis media;
- Lower respiratory tract infections - bacterial bronchitis and community acquired pneumonia;
- Skin and subcutaneous tissues - moderate acne vulgaris, erythema chronicum migrans (first stage of Lyme disease), erysipelas, impetigo and secondary pyoderma;
- Sexually transmitted diseases - uncomplicated urethritis and cervicitis caused by *Chlamydia trachomatis*.

The use of the product should be in line with national and local guidelines and recommendations for conducting antibacterial therapy.

6. Recommended Dose

Adults, including the elderly and children weighing more than 45 kg

- Upper and lower respiratory tract infections: Total course dose of 1500 mg, which should be taken for 3 days (500 mg once daily).
- Moderate acne vulgaris: Total course dose of 6 g, which should be taken under the following recommended dosage regime: 500 mg once daily for 3 consecutive days, 500 mg once weekly for the next 9 weeks. The dose for the second week should be taken 7 days after the administration of the first dose and the dose for the third to eighth weeks should be taken over 7-day intervals.
- Uncomplicated sexually transmitted diseases caused by *Chlamydia trachomatis*

The therapeutic dose is 1,000 mg, taken as a single dose.

- Erythema chronicum migrans (first stage of Lyme disease): Total course dose of 3 g azithromycin, which should be taken under the following dosage regime: a single daily dose of 1 g on Day 1, single daily doses of 500 mg on Days 2-5.

Children weighing less than 45 kg: Rominazit 500 mg capsules are not recommended in children weighing less than 45 kg, due to the lack of accurate dosing.

Renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance >40 ml/min).
Caution should be exercised in patients with severe renal impairment (creatinine clearance <40 ml/min) (see section 4.4).

Hepatic impairment: Since azithromycin is metabolised in the liver and excreted in the bile, the product is contraindicated in patients suffering from severe liver diseases. No studies have been conducted in relation to the use of azithromycin in this patient group.

Method of administration: Rominazit capsules should be swallowed whole, as a single daily dose. Like the other antibiotics, the product should be taken at least one hour before or two hours after meal.

7. Mode of Administration: Oral.

- **Contraindication:** Do not take Rominazit if you are allergic to azithromycin or any of the other ingredients of this medicine;
- if you are allergic to erythromycin or other antibiotics of the macrolide and ketolide group;
- if you are currently taking medicines containing ergot derivatives.

9. Warnings and Precautions:

Allergic reactions:

During the treatment with azithromycin, as with erythromycin and other macrolide antibiotics, serious allergic reactions may develop in rare cases, such as angioneurotic oedema and anaphylaxis (rarely fatal). In some of these reactions, recurrence of clinical symptoms may be observed, whereby a longer period of observation and treatment is necessary. In case of hypersensitivity reactions occurrence, the product should be discontinued and symptomatic treatment should be administered. Due to the long tissue half-life of azithromycin, the clinical symptoms of hypersensitivity reactions may persist even after cessation of the anti-allergic treatment.

Heart disorders

Prolonged cardiac repolarisation and QT-interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been observed in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at an increased risk of prolonged cardiac repolarisation. Therefore, azithromycin should be used with particular caution in patients with:

- congenital or acquired, clinically documented and confirmed prolongation of the QT-interval;
- cardiomyopathy, especially in case of existing heart failure;
- sinus bradycardia;
- existing symptomatic arrhythmia;
- current co-administration of other medicinal products known to prolong the QT-interval, such as anti-arrhythmics of classes IA and III, cisapride and terfenadine;
- electrolyte disturbances, particularly hypokalaemia, hypomagnesaemia and hypocalcaemia.

Superinfections: During the treatment with azithromycin, there is a possibility of developing superinfections, including fungal infections. As with other antibacterial products, monitoring for symptoms of superinfections caused by non-susceptible microorganisms, including fungi, is recommended while conducting treatment with azithromycin. Pseudomembranous colitis of varying severity may develop. Mild clinical forms usually do not occur after product discontinuation; moderate and severe forms require treatment with electrolyte solutions, amino acid solutions and those for parenteral nutrition, antibacterial agents with high antibacterial activity against *Clostridium difficile*. Cases of diarrhoea caused by *Clostridium difficile* (CDAD) have been reported with the use of almost all antibacterial agents, including azithromycin, as its severity may range from mild diarrhoea to fatal colitis leading to colectomy. CDAD must always be taken into consideration in patients in whom the antibiotic therapy is accompanied by the development of diarrhoea. Careful monitoring by a specialist is required, since CDAD may occur over two months after cessation of the antibiotic use.

Streptococcal infections: Penicillin is the first choice for the treatment of pharyngitis/tonsillitis caused by *Streptococcus pyogenes*, as well as for the prevention of acute rheumatic fever.

Azithromycin is usually effective against streptococci in the oropharynx, but there are no data to demonstrate its efficacy in the prevention of acute rheumatism.

Renal impairment: In patients with severe renal impairment (creatinine clearance <40 ml/min), increases by 33% in the systemic exposure to azithromycin have been observed. There are no clinical data on the safe use of azithromycin in patients with severe renal impairment and therefore, the product should be used with particular caution in such cases. No dose adjustment is required in moderate and mild renal impairment (creatinine clearance >40 ml/min).

Hepatic impairment: Patients with marked hepatic dysfunction and cholestasis require attention and limiting the treatment with azithromycin, having in mind that the elimination is carried out mainly by the liver. Treatment with azithromycin in patients with a severe liver disease requires caution, as there have been reports of fulminant hepatitis, potentially leading to life-threatening hepatic failure. The risk is higher in patients with pre-existing liver diseases or taking potentially hepatotoxic medicinal products. In case of clinical symptoms and/or clinical laboratory evidence of liver dysfunction, such as rapidly developing asthenia, accompanied by jaundice, dark urine, bleeding tendency or symptoms of hepatic encephalopathy, significant elevations of liver enzymes, prompt liver function tests/investigations should be performed and the administration of the product should be discontinued, if needed.

Treatment with ergot derivatives: In patients taking ergot derivative-containing medicines, the concomitant use of macrolide antibiotics accelerates the development of ergotism. There is no known evidence of such an interaction with azithromycin, but due to the existence of even a theoretical risk of such interaction, concomitant administration of azithromycin and ergolamine is unadvisable.

Myasthenia gravis: Cases of exacerbations of the disease or onset of myasthenia have been reported in patients treated with azithromycin.

Other: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product because it contains lactose monohydrate as an excipient.

The gelatin capsule contains the colourant azorubine, carmoisine (E122), which may cause allergic reactions.

10. Interaction With Other Medicaments

Antacids: Co-administration with aluminum or magnesium-containing antacids has not led to changes in the bioavailability of azithromycin, although has resulted in reduction of the peak plasma concentrations by approximately 25%. In view of these data, azithromycin should not be co-administered with antacids. Azithromycin intake should be at least 2 hours before or after the administration of antacids.

Cimetidine: Cimetidine, administered two hours before azithromycin, does not adversely affect pharmacokinetic behaviour of azithromycin.

Nefinavir: In a study of 12 healthy volunteers receiving concomitant azithromycin (1,200 mg) and nefinavir at the steady state (750 mg three times daily), 100% increase in azithromycin absorption and bioavailability has been found. No significant effect on the clearance has been reported. The clinical significance of this interaction is unknown, but caution is required in case of azithromycin administration in patients receiving nefinavir.

Terfenadine: Due to the risk of serious arrhythmias, leading secondarily to prolongation of the QT-interval in patients receiving other antibacterial agents concurrently with terfenadine, clinical trials were conducted to study the possible pharmacokinetic interactions. In the course of the studies, no evidence of interaction between azithromycin and terfenadine has been found. In some cases, it was not possible to exclude the possibility of such interactions, but no concrete evidence of their occurrence has been established. As with other macrolides, azithromycin should be used with particular caution in combination with terfenadine.

Fluconazole: In an open-label, randomized, cross-over study in 18 healthy volunteers, the effects of oral 1,200 mg dose of azithromycin were investigated on the pharmacokinetics of fluconazole, administered at 800 mg and vice versa.

No significant pharmacokinetic interactions between fluconazole and azithromycin have been found.

Rifabutin: During co-administration of azithromycin and rifabutin, the serum concentrations of both medicines were not affected. Neutropenia was found in individuals

concomitantly treated with azithromycin and rifabutin. Neutropenia was rather associated with the use of rifabutin, as no causal relationship to the combination with azithromycin has been established (see section 4.8).

Effects of azithromycin on other medicines

Carbamazepine: In a clinical study in healthy volunteers for determining the potential pharmacokinetic interactions upon co-administration of azithromycin and carbamazepine, no significant effect on plasma concentrations of carbamazepine or its active metabolites has been observed.

Cisapride: Cisapride is metabolised in the liver by the CYP 3A4. Because macrolide antibiotics inhibit these enzymes, co-administration of cisapride may cause prolongation of the QT-interval, ventricular arrhythmias and such of the torsades de pointes type.

Cyclosporine: In a pharmacokinetic clinical trial in healthy volunteers receiving 500 mg azithromycin for three days, followed by a single oral dose of 10 mg/kg cyclosporine, significant increases in C_{max} and AUC_{0-24} by 24% and 21%, respectively, have been found for cyclosporine. Significant changes in AUC_{0-24} have not been established.

These data require careful consideration on the appropriateness of co-administration of both products. If co-administration is required, cyclosporine levels should be monitored and the dose adjusted accordingly.

Digoxin: Some macrolide antibiotics have been reported to affect the microbial metabolism of digoxin in the intestines of some patients. The possibility of increased digoxin plasma concentrations in patients receiving concomitant azithromycin and digoxin should be taken into account. Monitoring of digoxin plasma levels should be considered.

Ergot derivatives: Due to an existing theoretical possibility of developing ergotism, azithromycin should not be co-administered with ergot derivative-containing products (see section 4.4).

Methylprednisolone: In a pharmacokinetic interaction clinical study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.

Theophylline: Upon co-administration, there was no evidence of untoward pharmacokinetic drug interactions.

Coumarin-type oral anticoagulants: In a clinical study, azithromycin did not alter the anticoagulant effect of a single 15 mg dose of warfarin administered to healthy volunteers.

There have been reports received from the post-marketing studies of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time, when azithromycin is used in patients receiving coumarin-type oral anticoagulants.

Zidovudine: Single 1,000 mg doses and multiple 1,200 mg or 600 mg doses of azithromycin had no effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolites. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine (the clinically active metabolite) in peripheral blood mononuclear cells. The clinical significance of this finding is unclear.

Didanosine: Co-administration of 1,200 mg/day azithromycin with didanosine in 6 patients did not appear to affect the pharmacokinetics of didanosine, compared with placebo.

Atorvastatin: Co-administration of azithromycin (500 mg daily) and atorvastatin (10 mg daily) did not alter the plasma concentrations of atorvastatin.

Cetirizine: Co-administration of a 5-day regimen of azithromycin with cetirizine (20 mg) at the steady-state resulted in no pharmacokinetic interaction and no significant prolongation of the QT-interval.

Efavirenz: Co-administration of a 600 mg single dose of azithromycin and 400 mg single dose of efavirenz for 7 days did not result in any clinically significant pharmacokinetic interactions.

Indinavir: Co-administration of a single dose of 1,200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered at 800 mg three times daily for 5 days.

Midazolam: Azithromycin, administered at the usual course dose (500 mg once daily for 3 consecutive days) did not result in untoward changes in the pharmacodynamics and pharmacokinetics of midazolam administered at a 15 mg dose.

Sildenafil: Administered at a single daily dose of 500 mg for 3 days, azithromycin did not affect the main pharmacokinetic parameters (AUC and C_{max}) of sildenafil or its major metabolite.

Triazolam: When co-administered with azithromycin (azithromycin of 500 mg on Day 1, 250 mg on Day 2 and 125 mg triazolam), there was no evidence of untoward drug pharmacokinetic interactions.

Trimoprim/sulfamethoxazole: When co-administered with azithromycin (rimethoprim/sulfamethoxazole of 160 mg/800 mg, respectively, plus azithromycin of 1,200 mg for 7 days), there was no evidence of untoward drug pharmacokinetic interactions.

11. Pregnancy and Lactation

Pregnancy: Studies on reproduction in animals are insufficient with respect to evaluation of effects on pregnancy, embryonal/foetal development, parturition or postnatal development. The potential risk for humans is unknown. There are no data from controlled clinical trials in humans. Azithromycin should not be used during pregnancy unless clearly needed.

Breast-feeding: There are insufficient, limited data on the excretion of azithromycin in human and mammalian milk. The risk to the infant cannot be ruled out. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from azithromycin therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the mother.

12. Undesirable Effects

The frequency grouping is defined using the following convention: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$); and not known (the frequency cannot be estimated from the available data).

Blood and lymphatic system disorders

Uncommon Leukopenia, neutropenia

Not known Thrombocytopenia, haemolytic anaemia

Cardiac disorders

Uncommon Palpitations

Not known Arrhythmia, including ventricular rhythm disorders, prolongation of the QT-interval, severe rhythm disorders of the torsade de pointes type

Ear and labyrinth disorders

Common Deafness

Uncommon Hearing impaired, tinnitus

Rare Vertigo

Gastro-intestinal disorders

Very common Diarrhoea, abdominal discomfort (pains/spasms), nausea, flatulence

Common Vomiting, dyspepsia

Uncommon Gastritis, constipation

Not known Pancreatitis, tongue discoloration

General disorders and administration site conditions

Common Fatigue

Uncommon Chest pain, oedema, malaise, asthenia

Hepatobiliary disorders

Uncommon Hepatitis

Rare Impaired hepatic function

Not known Hepatitis fulminant, cholestatic jaundice, hepatic necrosis, hepatic failure

Immune system disorders

Uncommon Angioedema, hypersensitivity reactions

Not known Anaphylactic reactions, including allergic shock (fatal in rare cases)

Infections and infestations

Uncommon Vaginitis, candidiasis (fungal infection)

Not known Pseudomembranous colitis

Musculoskeletal and connective tissue disorders

Common Arthralgia

Nervous system disorders

Common Headache, dizziness, paraesthesia, dysgeusia

Uncommon Hypoaesthesia, somnolence, insomnia

Not known Syncope, convulsions, psychomotor hyperactivity, anosmia, ageusia, parosmia, myasthenia gravis

Eye disorders

Common Vision impaired

Psychiatric disorders

Uncommon Nervousness

Rare Agitation

Not known Aggression, anxiety

Renal and urinary disorders

Not known Interstitial nephritis, acute renal failure

Skin and subcutaneous tissue disorders

Common Pruritus, rash

Uncommon Stevens-Johnson syndrome, photosensitivity, urticaria

Not known Toxic epidermal necrolysis, erythema multiforme

Metabolism and nutrition disorders

Common Anorexia

Vascular disorders

Not known Hypotension

Investigations

Common Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased

Uncommon ASAT increased, ALAT increased, blood bilirubin increased, blood urea increased, blood creatinine increased, blood potassium abnormal

Not known Prolonged QT-interval

13. Overdose and Treatment

Adverse events experienced in higher than recommended doses were similar to those seen at normal therapeutic doses. The typical symptoms of an overdose with macrolide antibiotics include loss of hearing, severe vomiting, nausea and diarrhoea. In the event of overdose, the administration of medicinal charcoal and general symptomatic treatment is required. Additional supportive measures should be considered with regard to vital functions.

14. Dosage Forms and packaging available

3 (three) hard gelatin capsules in a blister.

1 (one) blister with a package insert per carton.

15. Name and Address of Manufacturer/Marketing Authorisation Holder

Manufacturer:

BALKANPHARMA-RAZGRAD

68, Aprilsko Vastanie Blvd.

7200 Razgrad, Bulgaria

Marketing Authorisation Holder:

SPEY MEDICAL LTD.

Lynton House 7-12, Tavistock Square,

London, England, WC1H 9LT, United Kingdom

16. Date of Revision of Package Insert

01/2016

